DexCom (NASDAQ:DXCM – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
Risk & Volatility
DexCom has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
Earnings & Valuation
This table compares DexCom and Anteris Technologies Global”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DexCom | $4.66 billion | 5.97 | $836.30 million | $2.34 | 30.81 |
| Anteris Technologies Global | $1.91 million | 490.27 | -$94.14 million | ($2.23) | -4.31 |
DexCom has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
97.8% of DexCom shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares DexCom and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DexCom | 19.31% | 33.33% | 13.19% |
| Anteris Technologies Global | -5,148.78% | -124.76% | -101.21% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for DexCom and Anteris Technologies Global, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DexCom | 1 | 3 | 19 | 3 | 2.92 |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
DexCom currently has a consensus target price of $82.21, indicating a potential upside of 14.02%. Anteris Technologies Global has a consensus target price of $16.00, indicating a potential upside of 66.32%. Given Anteris Technologies Global’s higher possible upside, analysts clearly believe Anteris Technologies Global is more favorable than DexCom.
Summary
DexCom beats Anteris Technologies Global on 12 of the 15 factors compared between the two stocks.
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
